Fate Therapeutics, Inc. (FATE) NASDAQ
1.22
-0.02(-1.61%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.22
-0.02(-1.61%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.19 |
| Day High | 1.24 |
| Day Low | 1.18 |
| 52-Week High | 1.94 |
| 52-Week Low | 0.66 |
| Volume | 657,095 |
| Average Volume | 1.67M |
| Market Cap | 141.84M |
| PE | -1.06 |
| EPS | -1.15 |
| Moving Average 50 Days | 1.26 |
| Moving Average 200 Days | 1.16 |
| Change | -0.02 |
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 9:05 PM GMT
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapie
Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex-U.S. SLE patient treated with FT81
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell